

Resource Summary Report

Generated by [NIF](#) on Aug 20, 2026

p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb

RRID:AB_390779

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4695, RRID:AB_390779)

Antibody Information

URL: http://antibodyregistry.org/AB_390779

Proper Citation: (Cell Signaling Technology Cat# 4695, RRID:AB_390779)

Target Antigen: p44/42 MAPK (Erk1/2)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: WB, IP, IHC-P, IF-IC, FC-FP

Consolidation on 7/2016: AB_10831042

Info: Used By NYUIHC-973.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb

Description: This monoclonal targets p44/42 MAPK (Erk1/2)

Target Organism: Human, C. elegans, Rat, Bovine, Monkey, Zebrafish, Pig, Mouse, D. melanogaster, Mink, Dog, Hamster

Defining Citation: [PMID:23602964](#)

Antibody ID: AB_390779

Vendor: Cell Signaling Technology

Catalog Number: 4695

Alternative Catalog Numbers: 4695S, 4695P

Record Creation Time: 20260311T190852+0000

Record Last Update: 20260408T215529+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 797 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Liu J, et al. (2026) ERK1/2 hijack STAT3 via Thr714 phosphorylation to suppress gene expression. Cell communication and signaling : CCS, 24(1).

Chen X, et al. (2026) MiR-1202 increases radioresistance in nasopharyngeal carcinoma by targeting NAIF1/MAPK/ERK pathway. iScience, 29(4), 115135.

Freitas-Filho EG, et al. (2026) RAB5c orchestrates LC3-associated phagocytosis to promote microbicidal function of macrophages. Science advances, 12(19), eadz0196.

Balka KR, et al. (2026) Noncanonical IRF3 function mediates STING-dependent pro-inflammatory cytokine production in macrophages. EMBO reports, 27(11), 2865.

Yan X, et al. (2026) KRASG12/13 mutation modulates CRC outcomes via disrupting positive feedback between macrophage and CD4+ T cell. iScience, 29(1), 114402.

Chen M, et al. (2026) Macrophage migration inhibitory factor of zoonotic Giardia duodenalis triggers TLR4-MAPK/AKT/NLRP3 pathways to regulate inflammatory response. iScience, 29(1), 114404.

Zhang P, et al. (2026) SKA2 promotes gastric cancer progression by regulating glutathione metabolism. iScience, 29(4), 115202.

Fang K, et al. (2026) Pharmaco-genomic characterization of pancreatic and biliary tract cancer tumoroids for drug response. *iScience*, 29(3), 115062.

Radulovich N, et al. (2026) Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. *Cancer research communications*, 6(4), 832.

Wetterwald L, et al. (2026) MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion. *The Journal of experimental medicine*, 223(5).

Ni J, et al. (2026) CD70 regulates the NF1/Ras/ERK axis to promote metastatic potential in clear cell renal cell carcinoma. *Cancer cell international*, 26(1).

Li K, et al. (2026) Probiotics-enhanced kynurenic acid mitigates cisplatin-induced nephrotoxicity in mice. *iScience*, 29(3), 115053.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia (New York, N.Y.)*, 78, 101318.

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDI1 drives metastasis and chemoresistance in bladder cancer. *Cell reports*, 45(2), 116941.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. *Cancer research*, 86(15), 3666.

Kumari N, et al. (2026) Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 123(7), e2505331123.

Odeniyide P, et al. (2026) Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma. *Cancer research*, 86(10), 2508.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. *Cell reports*, 45(1), 116784.

Metz CN, et al. (2026) Leveraging Menstrual Effluent to Investigate Vitamin D and Human Decidualization: A Potential Link with Fertility. *The Journal of clinical endocrinology and metabolism*, 111(6), e1532.